Anna Postolova1,2, Megan L Troxell3,4, Irene L Wapnir3,4, Mark C Genovese3,4. 1. From the Division of Immunology and Rheumatology, Department of Pathology, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA. postolov@stanford.edu. 2. A. Postolova, MD, MPH, Fellow in Allergy/Immunology/Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; M.L. Troxell, MD, PhD, Professor of Pathology, Stanford University Medical Center; I.L. Wapnir, MD, Professor of Surgery, Department of Surgery, Stanford University School of Medicine; M.C. Genovese, MD, James W. Raitt Endowed Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine. postolov@stanford.edu. 3. From the Division of Immunology and Rheumatology, Department of Pathology, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA. 4. A. Postolova, MD, MPH, Fellow in Allergy/Immunology/Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; M.L. Troxell, MD, PhD, Professor of Pathology, Stanford University Medical Center; I.L. Wapnir, MD, Professor of Surgery, Department of Surgery, Stanford University School of Medicine; M.C. Genovese, MD, James W. Raitt Endowed Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine.
Abstract
OBJECTIVE: Idiopathic granulomatous mastitis (IGM) is a disfiguring inflammatory breast disease without effective treatment. We report the largest IGM cohort treated with methotrexate (MTX) monotherapy. METHODS: Chart review was performed on patients evaluated by the Stanford Immunology and Rheumatology Clinic, with histopathologically established IGM treated with MTX, and at least 1 followup appointment. RESULTS: Nineteen female patients with a mean age of 33.5 years were identified. Most failed treatment with antibiotics, prednisone, and surgical intervention. By 15 months of treatment with MTX, 94% had disease improvement and 75% achieved disease remission. CONCLUSION: MTX monotherapy is an effective treatment for IGM.
OBJECTIVE:Idiopathic granulomatous mastitis (IGM) is a disfiguring inflammatory breast disease without effective treatment. We report the largest IGM cohort treated with methotrexate (MTX) monotherapy. METHODS: Chart review was performed on patients evaluated by the Stanford Immunology and Rheumatology Clinic, with histopathologically established IGM treated with MTX, and at least 1 followup appointment. RESULTS: Nineteen female patients with a mean age of 33.5 years were identified. Most failed treatment with antibiotics, prednisone, and surgical intervention. By 15 months of treatment with MTX, 94% had disease improvement and 75% achieved disease remission. CONCLUSION: MTX monotherapy is an effective treatment for IGM.
Authors: Radjiv Goulabchand; Assia Hafidi; Philippe Van de Perre; Ingrid Millet; Alexandre Thibault Jacques Maria; Jacques Morel; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain Journal: J Clin Med Date: 2020-03-30 Impact factor: 4.964
Authors: Rami J Yaghan; Nehad M Ayoub; Shadi Hamouri; Alia Al-Mohtaseb; Maha Gharaibeh; Lamees Yaghan; Mahmoud Al-Dari; Hiba Al-Kaff; Nabil A Al-Zoubi Journal: Int J Breast Cancer Date: 2020-01-27